By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    bowl of vegetable salad
    Raw Foods: benefits and harms
    November 9, 2021
    pros and cons of the keto diet
    Read This Before You Follow the Keto Diet
    May 18, 2022
    spinal cord injuries
    4 Potential Causes of Spinal Cord Injuries (and How to Seek Compensation)
    May 25, 2022
    Latest News
    Emotional Peace: The Psychological Benefits Of Funeral Preplanning
    October 2, 2023
    Health Benefits of Taking a Vacation to Reduce Your Stress
    October 2, 2023
    First Aid Training Enhancing Workplace Health and Safety
    September 25, 2023
    Beyond the Clinic: Medical Surveys Are a Roadmap to Passive Income for Doctors
    September 23, 2023
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Why People Suffering from Chronic Pain Should Move to States that Legalized CBD
    December 31, 2018
    5 Things to Take Care of When You Go Into Hospital
    July 24, 2020
    4 Reasons Why Medical Device Compliance Matters
    May 22, 2020
    Latest News
    Job Seekers with Disabilities Should at Health Insurance Benefits
    September 12, 2023
    Reasons That Drug Prices Are Rising to Unsustainable Levels
    September 12, 2023
    How Revenue Lifecycle Management Helps Healthcare Providers to Optimize Business Operations
    September 6, 2023
    The Hidden Benefits of Practice Exams for Medical Professionals
    September 6, 2023
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: VIVUS, Inc., Presses the Case for Obesity Drug Qnexa, Market Success
Share
Sign In
Notification Show More
Aa
Health Works CollectiveHealth Works Collective
Aa
Search
Have an existing account? Sign In
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Global Healthcare > VIVUS, Inc., Presses the Case for Obesity Drug Qnexa, Market Success
Global Healthcare

VIVUS, Inc., Presses the Case for Obesity Drug Qnexa, Market Success

PatrickDriscoll
Last updated: 2011/10/18 at 7:08 AM
PatrickDriscoll
Share
3 Min Read
SHARE

Qnexa, a drug in development by VIVUS, is one of several promising drugs for the treatment of obesity that received adverse FDA decisions, but which are now receiving additional consideration for potential regulatory approval in exchange for completion of results that demonstrate positive outcomes relative to specific FDA concerns. 

From MedMarket Diligence Report #S835:

Qnexa, a drug in development by VIVUS, is one of several promising drugs for the treatment of obesity that received adverse FDA decisions, but which are now receiving additional consideration for potential regulatory approval in exchange for completion of results that demonstrate positive outcomes relative to specific FDA concerns. 

From MedMarket Diligence Report #S835:

More Read

US healthcare system

3 Ways to Improve the U.S. Healthcare System By 2030

6 Steps To Ensure Speed And Efficiency Of Clinical Studies
5 Most Valuable Healthcare Programs in 2023
The Everest Foundation’s Mission to Support Inclusive Healthcare
Using EHR systems in healthcare for Cost-Effective Services

Qnexa is an investigational, once a day, proprietary, oral, controlled-release formulation of low dose phentermine and topiramate. Vivus holds that this combination addresses the two main mechanisms that impact eating behavior: appetite and satiety.

In 2010, the FDA rejected Qnexa on the basis that evidence indicated it could cause birth defects in babies born to women who take the drug.  Responding specifically to these concerns, VIVUS has submitted a new application for Qnexa with a commitment to complete a clinical trial (called the “Fortress” trial) of Qnexa to assess fetal outcomes in offspring of women exposed to topiramate during the first trimester of pregnancy.  The initial results from the Fortress trial are due in December 2011.

Obesity drugs represent an enormous untapped opportunity based on their potential to produce significant weight loss without the need of bariatric surgery.  The realizable market for obesity drugs, encompassing satiety drugs, malabsorption drugs, appetite suppression drugs and combination drugs (like Qnexa) will reach almost $16 billion by 2019, while devices in the management of obesity will at that same time reach only $1.7 billion.

The FDA has recently made overtures in the obesity drug market that reflect an apparent recognition that adverse regulatory decisions in 2010 against Qnexa, Arena’s Lorcaserin and Orexigen’s Contrave may perhaps have overreached.


The MedMarket Diligence, LLC., Report #S835, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019”, is a global analysis of the clinical practice, products, technologies, companies and markets in the field of obesity. The report is described in detail at http://www.mediligence.com/rpt/rpt-s835.htm.

     

TAGGED: obesity, pharmaceuticals, Qnexa, VIVUS

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
PatrickDriscoll October 18, 2011 October 18, 2011
Share This Article
Facebook Twitter Copy Link Print
Share
By PatrickDriscoll
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Previous Article Physicians and HICS: Video
Next Article Why Not A Nurse?

Stay Connected

1.5k Followers Like
4.5k Followers Follow
2.8k Followers Pin
136k Subscribers Subscribe

Latest News

drug-free lifestyle
Healthy Routines Post-Rehab: Building A Drug-Free Lifestyle
Addiction Addiction Recovery October 2, 2023
emotional peace regarding funeral
Emotional Peace: The Psychological Benefits Of Funeral Preplanning
Wellness October 2, 2023
Andropause hormonal decline
The Benefits of TRT for Andropause and Hormonal Decline
Wellness September 28, 2023
cancer-prevention
The Importance of Lipoma Examination in Cancer Prevention
Cancer September 28, 2023

You Might also Like

Home Health Worker
Health care

Guarding Your Health – 6 Essential PPE Investments for the New Home Health Worker

August 31, 2023
conducting Clinical Trial
Global Healthcare

5 Tips for Conducting a Clinical Trial

July 26, 2023
Healthcare Providers
Global Healthcare

How Preventative Care Benefits Healthcare Providers

July 23, 2023
MRI sedation options
Global Healthcare

MRI Sedation Options: What You Should Know Before Screening

May 17, 2023
Subscribe

Subscribe to our newsletter to get our newest articles instantly!

Follow US
© 2008-2023 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Lost your password?